MGRX.NASDAQMangoceuticals, INC
10-Q: Mangoceuticals Reports Q1 2025 Results, Revenue Declines Amidst Platform Transition
Sentiment:
Quarterly Report
Mangoceuticals' Q1 2025 revenue decreased due to platform transition issues, while the company continues to pursue strategic alternatives and secure additional funding.
Capital raiseThe company is actively seeking additional funding through equity and debt financings to support operations and potential acquisitions.The company has availability of approximately $600,000 under the ELOC, which funding the company may request from the April 2024 Purchaser from time to time, subject to the terms thereof, and which funding, if requested may cause dilution to existing shareholders.Additionally, the company may receive funding upon the exercise of outstanding warrants from time to time, which exercises may cause dilution to existing shareholders.
Worse than expectedThe company's revenue decreased from Q1 2024 to Q1 2025.The company's net loss increased from Q1 2024 to Q1 2025.
Summary
- Mangoceuticals, Inc. reported a net loss of $4,839,489 for the three months ended March 31, 2025, compared to a net loss of $2,367,617 for the same period in 2024.
- Revenues decreased to $109,306 in Q1 2025 from $214,095 in Q1 2024, attributed to issues during the transition to a new telehealth platform.
- General and administrative expenses increased to $1,540,651 due to legal expenses, technology development costs, and expenses related to acquisitions and master distribution agreements.
- Advertising and marketing expenses decreased to $281,732 as the company focused on internal software development.
- The company is pursuing strategic alternatives to maximize shareholder value, including potential mergers, acquisitions, and business combinations.
- Mangoceuticals is actively seeking additional funding through equity and debt financings to support operations and potential acquisitions.
- The company has a working capital deficit of $1.36 million as of March 31, 2025, and needs additional funding to continue operations.
- The company is marketing and selling pharmaceutical products, including compounded products and PRIME by MangoRx, powered by Kyzatrex.
- The company entered into a Master Distribution Agreement with Navy Wharf, Ltd. for Diabetinol and with Propre Energie Inc. for Dermytol.
- The company purchased intellectual property from Smokeless Technology Corp. related to oral pouches as a delivery mechanism for nutritional and wellness products.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While the company is actively pursuing strategic alternatives and securing new agreements, the financial results show a decline in revenue and an increase in net loss, raising concerns about its financial stability.
Positives
- The company is actively pursuing strategic alternatives to maximize shareholder value.
- Mangoceuticals is seeking additional funding through equity and debt financings.
- The company entered into a Master Distribution Agreement with Navy Wharf, Ltd. for Diabetinol and with Propre Energie Inc. for Dermytol.
- The company purchased intellectual property from Smokeless Technology Corp. related to oral pouches as a delivery mechanism for nutritional and wellness products.
Negatives
- Q1 2025 revenue decreased to $109,306 from $214,095 in Q1 2024.
- Net loss for Q1 2025 increased to $4,839,489 from $2,367,617 in Q1 2024.
- The company has a working capital deficit of $1.36 million as of March 31, 2025.
- The company needs additional funding to continue operations.
Risks
- The company's ability to obtain additional funding is uncertain.
- The terms of any financing may adversely affect the holdings or rights of shareholders.
- The company may be forced to curtail its business plan if financing is unavailable.
- The company is subject to risks associated with its products not being approved by the FDA.
- The company is subject to risks associated with related party transactions.
- The company is subject to risks associated with potential stock manipulation.
Future Outlook
The company plans to continue using the same marketing and management strategies and continue providing a quality product with excellent customer service while also seeking to expand its operations organically or through acquisitions as funding and opportunities arise.
Industry Context
The company operates in the growing men's wellness telemedicine sector, focusing on erectile dysfunction, hair loss, testosterone replacement, and weight management treatments.
Comparison to Industry Standards
- The company's compounded products are produced at a related party compounding pharmacy using a proprietary combination of FDA approved ingredients.
- The company is marketing and selling an FDA approved form of oral testosterone undecanoate to treat low testosterone in men.
- The company is in the process of conducting Phase II clinical trials and efficacy studies to determine the effectiveness of its patented respiratory illness prevention technology.
- The company intends to license certain intellectual property and patent rights from Propre Energie, Inc. relating to clinically proven, plant-based formulations targeting hyperpigmentation, dark spots, uneven skin tone, and skin brightening through advanced solutions marketed under the brand Dermytol.
- The company intends to license certain intellectual property and patent rights from Navy Wharf, Ltd. relating to a clinically proven natural formula for a nutraceutical product to manage blood glucose and Hemoglobin A1c (HbA1c) levels to be marketed and sold under the brand Diabetinol, within the United States and Canada.
Legal Proceedings
- Eli Lilly and Company filed a complaint against the company in the Northern District of Texas Dallas Division alleging causes of action against us for false and misleading advertising and promotion in violation of Section 43(a)(1)(B) of the Lanham Act; and false advertising, in connection with the Companys TRIM product.
Related Party Transactions
- All Compounded Products are produced at and fulfilled by Epiq Scripts, LLC ( Epiq Scripts ), a related party compounding pharmacy, 52% owned by Jacob Cohen, our Chief Executive Officer and Chairman, and are available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient.
- During the three months ended March 31, 2025, Mr. Cohen used his personal credit card for payments to a third-party vendor for services rendered to the Company.
- On May 2, 2025, the Company borrowed $100,000 from The Tiger Cub Trust, which trust is controlled by the Companys Chief Executive Officer and Chairman, Jacob D. Cohen ( Tiger Cub ), and entered into a Promissory Note with Tiger Cub to evidence such loan.
Stakeholder Impact
- Shareholders may experience dilution due to potential equity financings.
- The company's ability to continue as a going concern is uncertain, which could impact stakeholders.
- The company's pursuit of strategic alternatives could lead to significant changes for stakeholders.
Next Steps
- Continue to make additional and ongoing technology enhancements to the platform.
- Further develop, market and advertise additional mens health and wellness related products on the telemedicine platform.
- Identify strategic acquisitions that complement the vision.
Key Dates
| Date | Description |
|---|---|
| 2021-10-07 | Mangoceuticals, Inc. was incorporated in the State of Texas. |
| 2022-08-16 | The Company initiated a private placement of up to $2 million of units to accredited investors. |
| 2023-03-01 | The Companys definitive proxy statement was filed with the Commission. |
| 2023-03-01 | The Company borrowed $37,500 from Ronin Equity Partners. |
| 2023-03-20 | The Company's Annual Report on Form 10-K for the year ended December 31, 2024, was filed with the Securities and Exchange Commission. |
| 2023-12-15 | The Company entered into an underwriting agreement with Boustead Securities, LLC. |
| 2023-12-19 | The Follow-On Offering closed. |
| 2024-01-18 | The Underwriters notified the Company that they were exercising their over-allotment option in full to purchase an additional 40,000 shares of common stock. |
| 2024-01-22 | The sale of the 40,000 shares of common stock closed. |
| 2024-03-18 | The Company borrowed $50,000 from Cohen Enterprises. |
| 2024-03-25 | Stockholders approved an amendment to effect a reverse stock split. |
| 2024-04-01 | The Company borrowed $100,000 from Cohen Enterprises. |
| 2024-04-04 | The Company agreed to definitive terms on a Securities Purchase Agreement. |
| 2024-04-05 | The Initial Closing Date of the Securities Purchase Agreement. |
| 2024-04-08 | The Company entered into an Equity Purchase Agreement with the Purchaser. |
| 2024-04-24 | The Company entered into a Patent Purchase Agreement with Intramont Technologies, Inc. |
| 2024-04-26 | The Company partially closed a planned second closing under the SPA. |
| 2024-04-28 | The Company and the Purchaser entered into an Omnibus Amendment Agreement No. 1. |
| 2024-05-17 | The Company closed the remaining portion of the Second Closing. |
| 2024-06-28 | The Company sold the Purchaser 750 shares of Series B Preferred Stock. |
| 2024-08-26 | The Company partially closed the Fourth Closing under the SPA. |
| 2024-09-26 | The Company partially closed the Fourth Closing under the SPA. |
| 2024-10-07 | The Companys Board of Directors approved an amendment to effect a reverse stock split of our common stock at a ratio of 1-for-15. |
| 2024-10-08 | We filed a Certificate of Amendment to our Certificate of Formation, as amended and restated with the Secretary of State of the State of Texas to affect the Reverse Stock Split. |
| 2024-10-16 | The Reverse Stock Split became effective. |
| 2024-10-18 | The Company entered into a $150,000 promissory note with Cohen Enterprises, Inc. |
| 2024-10-31 | Eli Lilly and Company filed a complaint against us in the Northern District of Texas Dallas Division. |
| 2024-12-13 | Mr. Cohen sold his note in the amount of $150,000 to a third party entity. |
| 2024-12-19 | The Company entered into a Patent Purchase Agreement with Greenfield Investments, Ltd. |
| 2025-01-09 | Mango & Peaches filed a Certificate of Designations of Mango & Peaches Corp. |
| 2025-01-15 | The Company sold the Purchaser the final 250 shares of Series B Preferred Stock. |
| 2025-01-15 | The Company entered into a Debt Conversion Agreement with Mill End. |
| 2025-01-30 | The Company entered into a Master Distribution Agreement with Propre Energie Inc. |
| 2025-02-11 | We and Intramont entered into a letter agreement, amending the Intramont IP Purchase Agreement. |
| 2025-02-12 | A holder of the Companys Series B Convertible Preferred Stock converted 216 shares of Series B Convertible Preferred Stock. |
| 2025-03-17 | The Company submitted to the Secretary of the State of Texas, an amendment to the Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc. |
| 2025-03-24 | The Company entered into a Master Distribution Agreement with Navy Wharf, Ltd. |
| 2025-03-25 | A holder of the Companys Series B Convertible Preferred Stock converted 146 shares of Series B Convertible Preferred Stock. |
| 2025-03-25 | A holder of the Companys Series B Convertible Preferred Stock converted 116 shares of Series B Convertible Preferred Stock. |
| 2025-03-25 | A holder of the Companys Series B Convertible Preferred Stock converted 350 shares of Series B Convertible Preferred Stock. |
| 2025-03-26 | A holder of the Companys Series B Convertible Preferred Stock converted 218 shares of Series B Convertible Preferred Stock. |
| 2025-03-28 | A holder of the Companys Series B Convertible Preferred Stock converted 74 shares of Series B Convertible Preferred Stock. |
| 2025-03-28 | A holder of the Companys Series B Convertible Preferred Stock converted 260 shares of Series B Convertible Preferred Stock. |
| 2025-03-28 | A holder of the Companys Series B Convertible Preferred Stock converted 58 shares of Series B Convertible Preferred Stock. |
| 2025-04-02 | MAAB Global Ltd. converted $500,000 of debt into 333,333 shares of the Companys common stock. |
| 2025-04-03 | A holder of the Companys Series B Convertible Preferred Stock converted 350 shares of Series B Convertible Preferred Stock. |
| 2025-04-08 | We entered into a Consulting Agreement with 2855322 Ontario Inc. |
| 2025-04-10 | Effective on April 10, 2025, the Company issued an aggregate of 335,000 fully-vested and earned shares of Company common stock. |
| 2025-04-11 | The Company agreed to definitive terms on a Securities Purchase Agreement. |
| 2025-04-15 | The Company borrowed $500,000 from Indigo Capital LP. |
| 2025-04-16 | We amended our Consulting Agreement with Spartan Crest Capital. |
| 2025-04-16 | We entered into a Consulting Agreement with Cardinal Advisors, Ltd. |
| 2025-04-18 | We entered into a Consulting Agreement with ArcStone Securities and Investments Corp. |
| 2025-04-24 | The Company entered into an Intellectual Property Purchase Agreement with Smokeless Technology Corp. |
| 2025-04-28 | A holder of the Companys Series B Convertible Preferred Stock converted 100 shares of Series B Convertible Preferred Stock. |
| 2025-05-01 | A holder of the Companys Series B Convertible Preferred Stock converted 300 shares of Series B Convertible Preferred Stock. |
| 2025-05-01 | We entered into a Consulting Agreement with LSTM Holdings, LLC. |
| 2025-05-02 | The Company borrowed $100,000 from The Tiger Cub Trust. |
| 2025-05-05 | The Company entered into a Compromise Settlement Agreement and Mutual Release. |
| 2025-05-13 | Mango & Peaches Corp. issued 4,892,906 shares of its common stock and 100 shares of its Series A Super Majority Voting Preferred Stock to Jacob Cohen. |
| 2025-05-14 | MangoRx IP Holdings, LLC entered into a Master Distribution Agreement with PrevenTech Solutions, LLC. |
Keywords
Mangoceuticals, financial results, Q1 2025, revenue, net loss, funding, strategic alternatives, telehealth, pharmaceutical products, Diabetinol, Dermytol, Smokeless Technology, intellectual property, master distribution agreement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.